chufangao/CTO huggingface dataset:
Clinical trial NCT01659658: Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Official title: A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 177.0 (ACTUAL)
Number of arms: 5.0
Start date: 2012-12-26
Primary completion date: 2022-07-11
Completion date: 2022-07-11
Baseline population: Intent-to-Treat (ITT) Population included all participants who were randomized.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04699461: Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Official title: A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)
Acronym: LOTIS-6
Sponsor: ADC Therapeutics S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Administrative decision (not due to safety reason)
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-04
Primary completion date: 2022-11-25
Completion date: 2022-11-25
Limitations and caveats: The study was terminated (administrative decision) by the sponsor following the withdrawal of idelalisib from the US market for the relapsed FL indication (i.e., not due to any safety reasons emerging from this study).
Plan to share individual participant data: NO
Clinical trial NCT02437084: Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Official title: Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 115.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-05-31
Primary completion date: 2020-02-29
Completion date: 2020-04-30
Baseline population: Participants who completed both baseline and end-of-study tests and did not receive treatment with a corticosteroid.
Limitations and caveats: Our study was a single-center trial with a single dose of atorvastatin without a placebo control group. The study was also short term and longer trials are needed to assess for potential decreases in insulin secretion or further increases in insulin resistance.
Plan to share individual participant data: NO
Clinical trial NCT03535740: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Official title: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Acronym: ALTA-2
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 103.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-31
Primary completion date: 2020-09-30
Completion date: 2024-08-21
Baseline population: Full Analysis Set (FAS) included all participants who received at least 1 dose of brigatinib.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04936841: Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
Official title: Phase II Study of Bempegaldesleukin (NKTR-214) Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: study closed by the sponsor
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-05
Primary completion date: 2022-10-04
Completion date: 2022-10-04
Limitations and caveats: Study terminated early by the sponsor
Plan to share individual participant data: NO
Clinical trial NCT04675996: First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors
Official title: Phase I/Ib, Open-label, Multiple Ascending Dose, First-in-Human Study, to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of INT-1B3 in Patients With Advanced Solid Tumors
Sponsor: InteRNA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: insufficient funding
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-18
Primary completion date: 2023-03-24
Completion date: 2023-03-24
Plan to share individual participant data: NO
Clinical trial NCT02649673: LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Official title: Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies
Sponsor: SCRI Development Innovations, LLC (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Clinical program was discontinued by Novartis
Enrollment: 34.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-03-23
Primary completion date: 2021-07-30
Completion date: 2021-07-30
Clinical trial NCT04209465: A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Official title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
Acronym: MasterKey-01
Sponsor: Black Diamond Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The development of BDTX-189 was discontinued by the sponsor.
Enrollment: 91.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-19
Primary completion date: 2022-09-02
Completion date: 2022-09-16
Plan to share individual participant data: NO
Clinical trial NCT03556202: A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
Official title: A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated due to a strategic business decision made by the Sponsor.
Enrollment: 1936.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-03
Primary completion date: 2022-02-07
Completion date: 2022-02-07
Baseline population: All randomized participants.
Limitations and caveats: This study was terminated before completion of the long-term extension trial, due to strategic business decision made by the company.
Plan to share individual participant data: YES
IPD sharing description: Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Clinical trial NCT02285543: A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
Official title: A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: No new participants could be enrolled.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-01
Primary completion date: 2023-07-30
Completion date: 2023-07-30
Clinical trial NCT03161574: FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
Official title: FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for MRI-defined Circumferential Radial Margin (CRM) Positive Rectal Cancer
Sponsor: Guangxi Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants were recruited
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-11
Primary completion date: 2019-12-01
Completion date: 2022-06-01
Plan to share individual participant data: NO
Clinical trial NCT03326128: High Dose Bupropion for Smoking Cessation - Pilot Study
Official title: High Dose Bupropion Treatment for Smoking Cessation - Pilot Study
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to the COVID-19 pandemic, it was difficult to recruit eligible participants.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2023-07-01
Completion date: 2023-07-01
Plan to share individual participant data: NO
Clinical trial NCT03829969: Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
Official title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy
Acronym: JUPITER06
Sponsor: Shanghai Junshi Bioscience Co., Ltd. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 514.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-31
Primary completion date: 2021-03-22
Completion date: 2023-09-30
Clinical trial NCT05108922: A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Official title: A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 148.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-16
Primary completion date: 2022-09-09
Completion date: 2023-09-19
Baseline population: All randomized participants who received at least one dose of study drug to donanemab or aducanumab.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT05060965: Inpatient Smoking Cessation Pilot Program
Official title: Smoking Cessation Pilot Program on 9 South
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No Enrollees
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-01
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Plan to share individual participant data: NO
IPD sharing description: De-identified participant data will be shared with researchers or sponsor upon review of a written request. The request will require a detailed description of the usage of the data and will require approval by the principal investigator. A data use agreement will be set-up and a plan for data removal (including timeline) will be established.
Clinical trial NCT03225846: Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
Acronym: PRECISION-HD2
Sponsor: Wave Life Sciences Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 88.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-07-17
Primary completion date: 2021-05-10
Completion date: 2021-05-10
Clinical trial NCT04427501: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
Official title: A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Acronym: BLAZE-1
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 3307.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-06-17
Primary completion date: 2023-02-21
Completion date: 2023-02-21
Baseline population: All randomized participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting
IPD access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting
Clinical trial NCT03324282: First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
Official title: Gemcitabine-cisplatin Plus Avelumab or Gemcitabine-cisplatin as First-line Treatment of Patients With Locally Advanced or Metastatic Urothelial Bladder Carcinoma (GCISAVE)
Acronym: GCISAVE
Sponsor: University Hospital, Bordeaux (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in recruitment, Most investigators would like to offer avelumab for maintenance, Absence of benefit to the chemo-immuno combination (pembro+gem-platinum) in phase III
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-23
Primary completion date: 2021-12-31
Completion date: 2022-01-14
Plan to share individual participant data: NO
Clinical trial NCT05073237: Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans
Official title: Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans
Acronym: CE/BZA
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-04-08
Primary completion date: 2024-04-08
Completion date: 2024-04-08
Plan to share individual participant data: NO
Clinical trial NCT04226365: Pediatric Concussion Outcomes
Official title: Treatment for Post-concussive Headache: A Randomized, Placebo-controlled, Double Blinded Trial
Acronym: PeCon
Sponsor: Lancaster General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was stopped prematurely due to a low enrollment rate.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-15
Primary completion date: 2023-05-31
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT04891185: Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer
Official title: Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer
Acronym: VIPIDO
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Clinical futility
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-01
Primary completion date: 2023-10-01
Completion date: 2023-10-01
Plan to share individual participant data: UNDECIDED
IPD sharing description: According to FAIR principle will data sharing be possible after conclusion of this trial.
Clinical trial NCT03982069: Immunologic Response to FluMist vs. Flucelvax
Official title: Immunological Response to Influenza Vaccination in Children, Adolescents, and Young Adults: A RCT of FluMist vs. Flucelvax
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 465.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-20
Primary completion date: 2020-12-09
Completion date: 2020-12-09
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in the primary article, after deidentification, will be placed at the site mentioned below.
IPD time frame: Beginning 9 months and ending 36 months after article publication.
IPD access criteria: Researchers who provide a methodologically sound proposal and have appropriate data security and privacy plans in place
Clinical trial NCT04920578: A Study of JNJ-69095897 in Healthy Participants
Official title: A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-69095897 in Healthy Participants
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: business decision to end clinical development of JNJ-69095897
Enrollment: 48.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-06-16
Primary completion date: 2023-01-27
Completion date: 2023-02-27
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02545361: Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Official title: A Phase 1/2a, Multi-center, Dose Escalation, 2 Stages Study to Evaluate the Safety, Tolerability, and Anti-cancer Activity of Subcutaneously Administered KAHR-102 for the Treatment of Lymphoma Patients Who Express Both B7 and FasR
Sponsor: Kahr Medical (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Program de-prioritized
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-30
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT05368402: Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Official title: Randomized, Placebo-controlled, Double-blinded, 2-parallel Arm, Clinical Trial Evaluating Ladarixin 400 mg Bid as Adjunctive Therapy to Improve Glycemic Control in Overweight Insulin-resistant Patients With Type 1 Diabetes.
Acronym: CONSERVA
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low recruitment rate
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-27
Primary completion date: 2023-09-18
Completion date: 2023-09-18
Plan to share individual participant data: NO
Clinical trial NCT03645057: ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis
Official title: ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-20
Primary completion date: 2021-08-01
Completion date: 2021-08-01
Plan to share individual participant data: NO
Clinical trial NCT03486587: A Study Evaluating Bacillus Cereus in the Prevention of Afatinib-associated Diarrhea
Official title: A Single-arm, Single-institutional, Phase II Study Evaluating the Efficacy and Safety of Bacillus Cereus (Changfukang®) in the Prevention of Afatinib-associated Diarrhea in NSCLC Patients
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Participants have better treatment selection, resulting in a slow recruitment.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-15
Primary completion date: 2020-08-31
Completion date: 2020-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03263780: High Resolution PET-MRI Before Prostate Cancer HIFU
Official title: High-Resolution, 18F-fluciclovine PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-07
Primary completion date: 2020-01-08
Completion date: 2020-01-08
Clinical trial NCT02489123: Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Official title: Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Accrual goal not met
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-08-11
Primary completion date: 2020-06-16
Completion date: 2020-06-16